Monoclonal antibody treatment may be the key to helping reduce the pressure that hospitals face during the surge in COVID-19 cases, but availability varies from state to state.
Three monoclonal antibody therapies have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (Food and Drug Administration) And they are currently managed for free. Monoclonal antibodies can help the human body fight COVID-19, and when used early, it has shown great hope to help prevent people from becoming seriously ill to the point of hospitalization.
Like any treatment, the power of monoclonal antibodies is limited. For example, it is most effective to use them as early as possible before viruses have a chance to develop. Therefore, the sooner a person is treated, the greater the chance of seeing the expected results.
Monoclonal antibody therapy is also limited to certain people, although it is a fairly wide range and does not depend on a person’s vaccination status. The FDA only approves this therapy for people over 12 years of age and people who are considered to be at high risk of serious illness. This high-risk group includes people over 65 years old, pregnant, suffering from multiple diseases, or obese or overweight.
Although many people do not think that they are overweight, according to the EUA, if a person’s BMI exceeds 25, which is just beyond the margin of health, they are eligible for treatment. BMI is calculated based on a person’s height and weight, so if a person is interested in monoclonal antibody therapy and is not eligible for other reasons, it is worth knowing a person’s BMI.
Monoclonal antibody therapy is most commonly used for people who test positive for COVID-19, but it is also used for prevention. As part of the FDA’s EUA, some individuals who have been exposed to COVID-19 but have not yet tested positive can be treated with monoclonal antibodies. In addition to being considered high-risk, a person cannot be fully vaccinated or cannot expect to have an adequate immune response after being fully vaccinated, such as a person with a weakened immune system.
Chandan Khanna/AFP/Getty Images
Eligibility for treatment is only part of the process, and there must be a place for treatment. If intravenous injection is not possible, it is administered by intravenous injection or multiple injections, and states have begun to set up clinics to help expand the use of treatment.
Department of Health and Human Services (HHS) website There are maps and a list of treatment locations. A person can enter their address, choose how many miles they are willing to drive from that location, and see which locations have received treatment goods. However, it does not guarantee that a certain location will provide treatment, so it is best to call that location before you arrive.
Some places do not accept patients without an appointment, and an appointment is required to receive treatment.
The National Association of Infusion Centers also has search The function provided on its website allows a person to enter their location and view nearby infusion centers. Another option for people is to visit the health department website in their state, because some people have carefully selected the list of treatment centers.
The EUA issued by the FDA allows treatment without approval. Only one therapy has received full FDA approval, and that is Redecivir, which is used in hospitalized patients.
Although monoclonal antibodies can help save lives and reduce hospital admissions, officials emphasize that they are different from vaccinations. One of the best ways to ensure that a person will not become seriously ill due to COVID-19 is to avoid contracting it, and vaccines have been shown to be safe and effective in preventing infection. Vaccines also help prevent the spread of the virus, thereby helping to limit the mutations that occur and reduce the chance that the variant will resist the vaccine or therapy.
Nevertheless, there are always people who will not or cannot be vaccinated, which makes the demand for outpatient treatment and preventive drugs an important supplement to the global pandemic response.
